Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage

NCT ID: NCT03271697

Last Updated: 2017-09-05

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-09-30
• Study Completion Date: 2020-09-30

Brief Summary

This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.

Detailed Description

Astragalus membranaceus (AM, Huang-Chi) is a Chinese herb used extensively in China as a traditional treatment to treat stroke for a long time, and a number of studies have shown that AM can reduce cerebral infarction area and has anti-oxidation activity. Our previous studies have demonstrated enhanced recovery of neurologic function in patients with acute hemorrhagic stroke who received AM. It is hypothesized that AM either reduces inflammatory response or reduces perihematomal edema.

Subarachnoid hemorrhage secondary to rupture of a cerebral aneurysm is a medical condition associated with a high morbidity and mortality; approximately 10-15% of patients die before reaching medical care, and overall mortality is approximately 45%. Of those that survive, 30% suffer permanent disability graded as moderate to severe, and two-thirds of survivors never return to the same quality of life as they had prior to their hemorrhage. A large number of patients (30-70%) who are able to make it to the hospital and have successful treatment of their aneurysm will develop delayed cerebral vasospasm that is related to the blood clot from their initial aneurysm rupture. Of patients that survive their initial aneurysm rupture, vasospasm results in an additional 7% mortality and another 7% of severe disabilities secondary to ischemic strokes from severe spasm of cerebral arteries.

This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients. All procedures done as a part of this study are standard hospital care procedures done to treat aneurysmal subarachnoid hemorrhage according to the AHA/ASA guideline.

Conditions

Aneurysmal Subarachnoid Hemorrhage

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

AM group

Treatment group will accept Astragalus Membranaceus(AM) t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.

Group Type: EXPERIMENTAL

Astragalus Membranaceus

Intervention Type: DRUG

This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.

Placebo group

Control group will accept placebo t.i.w treatment for 14 days from the second day of admission, in addition to standard ordinary treatment.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

as a comparator comparing with AM group

Interventions

Astragalus Membranaceus

This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.

Intervention Type: DRUG

Placebo

as a comparator comparing with AM group

Intervention Type: DRUG

Other Intervention Names

Astragalus propinquus; Starch

Eligibility Criteria

Inclusion Criteria

• Patients who admitted to the hospital within 24 hours of onset of aneurysmal subarachnoid hemorrhage (SAH) stroke
• Subarachnoid hemorrhage documented on head CT
• Hunt Hess Grade 1-4
• Both Male and Female
• Age more than 20 and less than 80 years older
• Informed consent obtained from a patient or legal representative before enrollment

Exclusion Criteria

• Traumatic or mycotic aneurysms
• Complication of serious heart or hepatic disease or infection or renal failure
• Malignant tumor
• Patients judged to be inappropriate by physician in charge
• Pregnant / breast feeding women
• Patients have enrolled or have not yet completed other investigational drug trials within 1 month before screening
• Ever stroke, and mRS≧3

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

China Medical University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Chun-Chung Chen

Attending Surgeon

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

CMUH106-REC1-074

Identifier Type: -

Identifier Source: org_study_id